Cytokines and autoimmunity: Redundancy defines their complex nature

Current Opinion in Immunology

Volumn 15, Issue 6, 2003, Pages 697-703

  Yadav, Deepak ^a   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 27; INTERLEUKIN 28; INTERLEUKIN 29; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; PROTEIN P50; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; COMPLEX FORMATION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MEDIATOR RELEASE; MYASTHENIA GRAVIS; NONHUMAN; PROTEIN FAMILY; RECEPTOR OCCUPANCY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

EID: 0242407712     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2003.09.006     Document Type: Review

References (70)

1. Mullen A.C., High F.A., Hutchins A.S., Lee H.W., Villarino A.V., Livingston D.M., Kung A.L., Cereb N., Yao T.P., Yang S.Y., et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 292:2001;1907-1910.
2. Alleva D.G., Pavlovich R.P., Grant C., Kaser S.B., Beller D.I. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor α and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes. 49:2000;1106-1115.
3. Liu J., Beller D.I. Distinct pathways for NF-κB regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains. J Immunol. 170:2003;4489-4496 By taking diabetes- and lupus-prone strains as examples, this study shows that alterations in NF-κB metabolism may be responsible for intrinsic IL-12 defects leading to autoimmunity.
4. Liu J., Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-κB expression and binding to the IL-12 p40 promoter. J Immunol. 169:2002;581-586.
5. Eaton A.D., Xu D., Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology. 108:2003;196-203.
6. Zhang G.X., Xu H., Kishi M., Calida D., Rostami A. The role of IL-12 in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J Immunol. 168:2002;2501-2507.
7. + T cells requires a third signal that can be provided by IL-12. J Immunol. 168:2002;5521-5529.
8. + T cell homeostatic expansion. J Immunol. 166:2001;5515-5521.
9. + T cell effectors that cause myocarditis. J Clin Invest. 111:2003;671-680.
10. Gran B., Zhang G.X., Yu S., Li J., Chen X.H., Ventura E.S., Kamoun M., Rostami A. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol. 169:2002;7104-7110.
11. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest. 110:2002;493-497.
12. Zhang G.X., Gran B., Yu S., Li J., Siglienti I., Chen X., Kamoun M., Rostami A. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-β2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol. 170:2003;2153-2160.
13. Brok H.P., van Meurs M., Blezer E., Schantz A., Peritt D., Treacy G., Laman J.D., Bauer J., t' Hart B.A. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol. 169:2002;6554-6563.
14. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13:2000;715-725.
15. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 168:2002;5699-5708.
16. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421:2003;744-748 This study clearly describes a typical example of receptor-mediated redundancy associated with cytokine behavior. IL-23, which shares its p40 subunit with IL-12, has been found to be the critical factor in mediating autoimmune inflammation of the brain. The other important finding of this paper is that, unlike IL-12, IL-23 acts an end-stage effector cytokine and has direct activity on memory T cells.
17. Murphy C.A., Hoek R.M., Wiekowski M.T., Lira S.A., Sedgwick J.D. Interactions between hemopoietically derived TNF and central-nervous-system- resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J Immunol. 169:2002;7054-7062.
18. Christadoss P., Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol. 122:2002;186-190.
19. Christen U., Wolfe T., Mohrle U., Hughes A.C., Rodrigo E., Green E.A., Flavell R.A., von Herrath M.G. A dual role for TNF-α in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol. 166:2001;7023-7032.
20. + T cells.
21. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 275:2000;768-775.
22. + Treg cell levels. Blockade of TRANCE-RANK causes a decreased frequency of the Treg cells and consequently leads to autoimmune diabetes.
23. Christen U., Von Herrath M.G. Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-α expression at a time when the autoimmune process is already ongoing. Ann N Y Acad Sci. 958:2002;166-169.
24. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 50:2002;206-211.
25. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., Erb K., Schuler G., Lutz M.B. Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J Exp Med. 195:2002;15-21.
26. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2:2002;364-371.
27. Kroesen S., Widmer A.F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxford). 42:2003;617-621.
28. Debandt M., Vittecoq O., Descamps V., Le Loet X., Meyer O. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol. 22:2003;56-61.
29. Lee D.U., Agarwal S., Rao A. Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity. 16:2002;649-660.
30. Fallon P.G., Jolin H.E., Smith P., Emson C.L., Townsend M.J., Fallon R., McKenzie A.N. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity. 17:2002;7-17 This study provides critical insights into the functioning of Th2 cytokines (IL-4,IL-5,IL-9 and IL-13). Interestingly, IL-4 could still evoke all Th2 effector functions even in the combined absence of other key Th2 cytokines. This study clearly shows the pivotal role played by IL-4 in modulating Th2 effector function.
31. + T cells and hence to clinical improvement.
32. Rudge E.U., Cutler A.J., Pritchard N.R., Smith K.G. Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and FcγRII-mediated B-cell suppression. J Exp Med. 195:2002;1079-1085.
33. Morris S.C., Dragula N.L., Finkelman F.D. IL-4 promotes Stat6-dependent survival of autoreactive B cells in vivo without inducing autoantibody production. J Immunol. 169:2002;1696-1704.
34. + T cells to the target (pancreas). On the other hand pancreatic Th1 (IFN-γ) expression is linked to a significantly higher recruitment of autoreactive cells, thus leading to autoimmune diabetes.
35. Finnegan A., Grusby M.J., Kaplan C.D., O'Neill S.K., Eibel H., Koreny T., Czipri M., Mikecz K., Zhang J. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol. 169:2002;3345-3352.
36. Svensson L., Nandakumar K.S., Johansson A., Jansson L., Holmdahl R. IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis. Eur J Immunol. 32:2002;2944-2953.
37. Nagayama Y., Mizuguchi H., Hayakawa T., Niwa M., McLachlan S.M., Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol. 170:2003;3522-3527.
38. Dogan R.N., Vasu C., Holterman M.J., Prabhakar B.S. Absence of IL-4, and not suppression of the Th2 response, prevents development of experimental autoimmune Graves' disease. J Immunol. 170:2003;2195-2204.
39. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 4:2003;63-68.
40. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 4:2003;69-77.
41. + T cell activation state characterized by the production of interleukin-17. J Biol Chem. 278:2003;1910-1914.
42. Wiekowski M.T., Leach M.W., Evans E.W., Sullivan L., Chen S.C., Vassileva G., Bazan J.F., Gorman D.M., Kastelein R.A., Narula S., et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol. 166:2001;7563-7570.
43. + T cells, and also that it synergizes with IL-12 in inducing IFN-γ production by these cells.
44. Yoshida H., Hamano S., Senaldi G., Covey T., Faggioni R., Mu S., Xia M., Wakeham A.C., Nishina H., Potter J., et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 15:2001;569-578.
45. Chen Q., Ghilardi N., Wang H., Baker T., Xie M.H., Gurney A., Grewal I.S., de Sauvage F.J. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 407:2000;916-920.
46. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 19:2001;683-765.
47. Dumoutier L., Leemans C., Lejeune D., Kotenko S.V., Renauld J.C. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 167:2001;3545-3549.
48. Wang M., Tan Z., Zhang R., Kotenko S.V., Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem. 277:2002;7341-7347.
49. Liao Y.C., Liang W.G., Chen F.W., Hsu J.H., Yang J.J., Chang M.S. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α J Immunol. 169:2002;4288-4297.
50. Blumberg H., Conklin D., Xu W.F., Grossmann A., Brender T., Carollo S., Eagan M., Foster D., Haldeman B.A., Hammond A., et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 104:2001;9-19.
51. Fickenscher H., Hor S., Kupers H., Knappe A., Wittmann S., Sticht H. The interleukin-10 family of cytokines. Trends Immunol. 23:2002;89-96.
52. Jiang H., Su Z.Z., Lin J.J., Goldstein N.I., Young C.S., Fisher P.B. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci U S A. 93:1996;9160-9165.
53. Wolk K., Kunz S., Asadullah K., Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 168:2002;5397-5402 In this paper, immune cells have been described as major source of the IL-10 family of cytokines, but appear to be a minor target for these cytokines.
54. Caudell E.G., Mumm J.B., Poindexter N., Ekmekcioglu S., Mhashilkar A.M., Yang X.H., Retter M.W., Hill P., Chada S., Grimm E.A. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 168:2002;6041-6046.
55. Schaefer G., Venkataraman C., Schindler U. Cutting edge: FISP (IL-4-induced secreted protein), a novel cytokine-like molecule secreted by Th2 cells. J. Immunol. 166:2001;5859-5863.
56. Parrish-Novak J., Xu W., Brender T., Yao L., Jones C., West J., Brandt C., Jelinek L., Madden K., McKernan P.A., et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem. 277:2002;47517-47523 Despite receptor-complex redundancy, the unique functions of IL-19, IL-20 and IL-24 have been ascribed to differences in signal transduction and ligand/receptor interactions.
57. Dumoutier L., Van Roost E., Colau D., Renauld J.C. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as a hepatocyte-stimulating factor. Proc Natl Acad Sci U S A. 97:2000;10144-10149.
58. Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z., Stinson J., Wood W.I., Goddard A.D., Gurney A.L. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem. 275:2000;31335-31339.
59. Lecart S., Morel F., Noraz N., Pene J., Garcia M., Boniface K., Lecron J.C., Yssel H. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol. 14:2002;1351-1356.
60. Nagem R.A., Colau D., Dumoutier L., Renauld J.C., Ogata C., Polikarpov I. Crystal structure of recombinant human interleukin-22. Structure (Camb). 10:2002;1051-1062.
61. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 277:2002;33676-33682.
62. Aggarwal S., Xie M.H., Maruoka M., Foster J., Gurney A.L. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res. 21:2001;1047-1053.
63. Baeza N., Sanchez D., Christa L., Guy-Crotte O., Vialettes B., Figarella C. Pancreatitis-associated protein (HIP/PAP) gene expression is upregulated in NOD mice pancreas and localized in exocrine tissue during diabetes. Digestion. 64:2001;233-239.
64. Knappe A., Hor S., Wittmann S., Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol. 74:2000;3881-3887.
65. Goris A., Marrosu M.G., Vandenbroeck K. Novel polymorphisms in the IL-10 related AK155 gene (chromosome 12q15). Genes Immun. 2:2001;284-286.
66. Haddad W., Cooper C.J., Zhang Z., Brown J.B., Zhu Y., Issekutz A., Fuss I., Lee H., Kansas G.S., Barrett T.A. P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med. 198:2003;369-377.
67. Takeda A., Hamano S., Yamanaka A., Hanada T., Ishibashi T., Mak T.W., Yoshimura A., Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 170:2003;4886-4890.
68. Kopp T., Lenz P., Bello-Fernandez C., Kastelein R.A., Kupper T.S., Sting G. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol. 170:2003;5438-5444.
69. Liu L, Ding C, Zeng W, Heuer JG, Tetreault JW, Noblitt TW, Hangoc G, Cooper S, Brune KA, Sharma G et al.: Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood 2003, in press.
70. Wei C.C., Ho T.W., Liang W.G., Chen G.Y., Chang M.S. Cloning and characterization of mouse IL-22 binding protein. Genes Immun. 4:2003;204-211.